Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 29, 2011

View Archived Issues

Chinese study reveals biomarker of stage B heart failure

Angiotensin AT1 receptor ligand rapidly lowers blood pressure in model of acute heart failure

Roche discovers long-acting agent with potential to treat neurological disorders

BiTE antibody shows promise to treat diffuse large B-cell lymphoma

Clinical studies assess prasugrel in sickle cell disease

New inhibitors of sclerostin prepared in Hong Kong

Aska Pharmaceutical discloses novel histamine H1 receptor antagonists

New sigma non-opioid intracellular receptor 1 ligands patented

Immunomedics and UCB amend epratuzumab license agreement

United Therapeutics gives regulatory update on treprostinil products

New antimicrobial peptides designed in Germany

U.K. study uncovers new putative biomarker of pulmonary arterial hypertension

Prosidion claims novel GPR119 receptor agonists/DPP IV inhibitors

Neuralstem clear to advance NSI-189 in major depressive disorder

Orally formulated neuroregenerative peptide set for clinical testing

Enrollment complete in second phase III tavaborole trial

Eisai resubmits perampanel NDA

FDA accepts NDA for Quad HIV regimen

TiGenix obtains funds for development of rheumatoid arthritis treatment

Marina Biotech and Mirna Therapeutics enter agreement for microRNA-based drugs

Noven Pharmaceuticals reports phase III data on low-dose paroxetine mesilate

Impax Pharmaceuticals files NDA for Parkinson's disease pill

Progen to switch formulation of potential best-in-class heparanase inhibitor

Quidel flu assay clear for use in U.S.

Meridian Bioscience receives FDA clearance for rapid test to detect CDI

New study investigates fixed-dose combination therapies for elevated IOP

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...